227 related articles for article (PubMed ID: 21463139)
1. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
Oudard S
Future Oncol; 2011 Apr; 7(4):497-506. PubMed ID: 21463139
[TBL] [Abstract][Full Text] [Related]
2. Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Sartor AO
J Hematol Oncol; 2011 Apr; 4():18. PubMed ID: 21513551
[TBL] [Abstract][Full Text] [Related]
3. Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Pal SK; Twardowski P; Sartor O
Clin Interv Aging; 2010 Dec; 5():395-402. PubMed ID: 21152241
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
Zhong L; Pon V; Srinivas S; Nguyen N; Frear M; Kwon S; Gong C; Malmstrom R; Wilson L
PLoS One; 2013; 8(5):e64275. PubMed ID: 23717582
[TBL] [Abstract][Full Text] [Related]
5. Reversal of docetaxel resistance with bevacizumab and thalidomide.
Ning YM; Figg WD; Dahut WL
Clin Genitourin Cancer; 2009 Aug; 7(2):E37-8. PubMed ID: 19692321
[TBL] [Abstract][Full Text] [Related]
6. Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer.
Nightingale G; Ryu J
P T; 2012 Aug; 37(8):440-8. PubMed ID: 23091336
[TBL] [Abstract][Full Text] [Related]
7. Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
Pal SK; Sartor O
Asian J Androl; 2011 Sep; 13(5):683-9. PubMed ID: 21602834
[TBL] [Abstract][Full Text] [Related]
8. Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
Dorff TB; Quinn DI
Ann Oncol; 2013 Feb; 24(2):270-272. PubMed ID: 23341479
[No Abstract] [Full Text] [Related]
9. Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Tagawa ST; Beltran H
Asian J Androl; 2011 Nov; 13(6):785-6. PubMed ID: 21857690
[No Abstract] [Full Text] [Related]
10. Current treatment strategies for castration-resistant prostate cancer.
Kim SJ; Kim SI
Korean J Urol; 2011 Mar; 52(3):157-65. PubMed ID: 21461278
[TBL] [Abstract][Full Text] [Related]
11. The evolution of chemotherapy for the treatment of prostate cancer.
Quinn DI; Sandler HM; Horvath LG; Goldkorn A; Eastham JA
Ann Oncol; 2017 Nov; 28(11):2658-2669. PubMed ID: 29045523
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.
Calcagno F; Nguyen T; Dobi E; Villanueva C; Curtit E; Kim S; Montcuquet P; Kleinclauss F; Pivot X; Thiery-Vuillemin A
Clin Med Insights Oncol; 2013; 7():1-12. PubMed ID: 23362372
[TBL] [Abstract][Full Text] [Related]
13. Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer.
Francini E; Ou FS; Rhoades J; Wolfe EG; O'Connor EP; Ha G; Gydush G; Kelleher KM; Bhatt RS; Balk SP; Sweeney CJ; Adalsteinsson VA; Taplin ME; Choudhury AD
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439209
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.
Wang JQ; DeChalus A; Chatterjee DN; Keller ET; Mizokami A; Camussi G; Mendelsohn AR; Renzulli Ii JF; Quesenberry PJ; Chatterjee D
Crit Rev Oncog; 2015; 20(5-6):407-17. PubMed ID: 27279238
[TBL] [Abstract][Full Text] [Related]
15. Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.
Antonarakis ES; Eisenberger MA
J Clin Oncol; 2013 May; 31(14):1709-12. PubMed ID: 23569320
[No Abstract] [Full Text] [Related]
16. Recent progress in nanoformulations of cabazitaxel.
Chen Y; Pan Y; Hu D; Peng J; Hao Y; Pan M; Yuan L; Yu Y; Qian Z
Biomed Mater; 2021 Feb; ():. PubMed ID: 33545700
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer.
Barata P; Ledet E; Manogue C; Cotogno P; Harris K; Lewis B; Layton J; Sartor O
Oncologist; 2020 Sep; 25(9):e1421-e1422. PubMed ID: 32592623
[No Abstract] [Full Text] [Related]
18. Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
Blas L; Shiota M; Tanegashima T; Kobayashi S; Matsumoto T; Eto M
Int J Urol; 2024 Mar; ():. PubMed ID: 38441353
[No Abstract] [Full Text] [Related]
19. Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
Yamamoto Y; Nonomura N
Int J Urol; 2024 Apr; ():. PubMed ID: 38572670
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
